Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023418 (leukemia)
 93,477 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Internal tandem duplication mutations of FMS-like tyrosine kinase-3 (FLT3) have been associated with poor outcomes in acute myelogenous leukemia. Over the course of the last several years, multiple agents have been developed and studied as potential inhibitors of FLT3 with the hope of providing clinical benefit for these patients. Lestaurtinib, a multi-targeted indolocarbazole derivative that potently inhibits FLT3 autophosphorylation in vitro, has been the most extensively studied agent in clinical trials to date. Multiple late-phase trials are underway to study this agent in adult and pediatric leukemia. This article will summarize the historical development of the pharmacology of lestaurtinib, as well as the ongoing investigation of the agent in preclinical and clinical studies.
 ...
PMID:Lestaurtinib: a multi-targeted FLT3 inhibitor. 2108 90